

# Bastien Nguyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5346978/publications.pdf>

Version: 2024-02-01

29  
papers

1,357  
citations

394390

19  
h-index

580810

25  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	7.0	28
2	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	1.9	40
3	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
4	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
5	Genomic landscape of endometrial carcinomas of no specific molecular profile. <i>Modern Pathology</i> , 2022, 35, 1269-1278.	5.5	33
6	The Impact of PIK3R1 Mutations and Insulinâ€™PI3Kâ€™ Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	7.0	7
7	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	1.4	2
8	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021, 11, 9478.	3.3	9
9	Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 70.	5.4	8
10	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
11	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	7.3	73
12	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1844-1856.	1.1	83
13	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	12.8	46
14	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3230-3238.	7.0	112
15	37. Spatiotemporal patterns of metastatic spread and survival from MSK-IMPACT, a large-scale prospective clinical sequencing. <i>Cancer Genetics</i> , 2020, 244, 14.	0.4	0
16	Characteristics and Outcome of <i>AKT1</i> E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020, 10, 526-535.	9.4	36
17	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	1.9	72
18	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	3.0	93

#	ARTICLE	IF	CITATIONS
19	Abstract 1308:CDK12alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics. , 2020, , .		0
20	Young Age and Breast Cancer Biology. , 2020, , 13-22.		0
21	Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811982839.	3.9	22
22	Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 742-746.	6.3	40
23	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. Breast Cancer Research, 2019, 21, 25.	5.0	22
24	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research, 2019, 21, 151.	5.0	30
25	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. Npj Breast Cancer, 2018, 4, 23.	5.2	26
26	Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer. , 2018, , .		4
27	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews, 2016, 49, 65-76.	7.7	167
28	Genomic aberrations in young and elderly breast cancer patients. BMC Medicine, 2015, 13, 266.	5.5	80
29	The pattern of somatic mutations and chromosomal copy number variations (CNV) in young breast cancer (BC) patients (pts).. Journal of Clinical Oncology, 2015, 33, 579-579.	1.6	2